Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

Huh? Original poster presentation for K shows p21 increases, dose dependent ,that were large. Cannot recall percentages off top of head but a lot. Easy to look up.

All this likely means is that cohort doses must be higher to see an impact on p21/PUMA etc. (Not at all a surprise)

But it does mean that reported changes in p21 are unimpressive for early cohorts.

Is there any other poster argue that would otherwise?

The relative importance of all of this- rise of p21, PUMA MDM2 ratios- is certainly up for debate.

Would love to know about what actual patients are experiencing.